Summary
A clinical development plan specific to children is a necessary component of every development plan for a new antiepileptic drug (AED). In the last decade, considerable discussion has occurred in the medical and regulatory communities, resulting in specific pediatric drug development legislation. Ethical issues are a foremost consideration in the design and conduct of studies. The timing of clinical studies differs between adults and children. In general, studies in children will not be performed until efficacy and safety has been demonstrated in adults. Exceptions include development of AEDs for seizure types seen only in children. Formulation preparation and dosing selection are often more challenging in children. Clinical trials including pharmacokinetic studies will be conducted in patients. A relatively small number of children, given subdivision into age groups and seizure types, are available for study. Clinical trials must be designed with children in mind, adjusting the length of the trials and the choice of controls. Efficacy extrapolation from adults may be considered for partial seizures in children, but not in infants. Seizure counts remain an appropriate efficacy endpoint; however, ascertainment in infants and younger children may require EEG monitoring. Safety specific to growing and developing children must be evaluated and long-term effects monitored.
Key Words: Epilepsy, children, antiepileptic drugs, clinical development
References
- 1.Pellock JM. Pediatric trials: practical issues. Special populations and trial designs. Adv Neurol. 1998;76:167–171. [PubMed] [Google Scholar]
- 2.Guidance for Industry: Ell clinical investigation of medicinal products in the pediatric population. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologies Evaluation and Research. December 2000. Available at: http://www.fda.gov/cder/guidance/4099fnl.pdf.
- 3.Best Pharmaceuticals for Children Act (BPCA). Public Law 107–109. January 4, 2002. Available at: http://thomas.loc.gov/bss/dl07/d1071aws.html.
- 4.Pediatric Research Equity Act (PREA). Public Law 108–155. December 3, 2003. Available at: http://thomas.loc.gov/bss/d108/d1081aws.html.
- 5.Additional safeguards for children in clinical investigations of FDA-regulated products. U.S. Department of Health and Human Services, Food and Drug Administration. April 2001. 66 Federal Register 20589-20600. Available at: http://www.fda.gov/ohrms/dockets/98fr/042401a.htm. [PubMed]
- 6.Commission on Antiepileptic Drugs of the International League of Epilepsy Workshop on antiepileptic drug trials in children. Epilepsia. 1991;32:284–285. doi: 10.1111/j.1528-1157.1991.tb05257.x. [DOI] [PubMed] [Google Scholar]
- 7.Sheridan PH, Jacobs MP. The development of antiepileptic drugs for children. Report from the NIH workshop, Bethesda, Maryland, February 17–18, 1994. Epilepsy Res. 1996;23:87–92. doi: 10.1016/0920-1211(95)00043-7. [DOI] [PubMed] [Google Scholar]
- 8.European Medicines Agency (Paediatric Working Party, Quality Working Party) Reflection paper: formulations of choice for the paediatric population. EMEA/CHMP/PEG/194810/2005. London: European Medicines Agency; 2006. [Google Scholar]
- 9.Ouellet D, Bockbrader HN, Wesche DL, Shapiro DY, Garofalo E. Population pharmacokinetics of gabapentin in infants and children. Epilepsy Res. 2001;47:229–241. doi: 10.1016/S0920-1211(01)00311-4. [DOI] [PubMed] [Google Scholar]
- 10.Hauser WA. The prevalence and incidence of convulsive disorders in children. Epilepsia. 1994;35(Suppl 2):S1–S6. doi: 10.1111/j.1528-1157.1994.tb05932.x. [DOI] [PubMed] [Google Scholar]
- 11.Camfield PR, Camfield CS, Gordon K, Dooley JM. If a first antiepileptic drug fails to control a child’s epilepsy, what are the chances of success with the next drug? J Pediatr. 1997;131:821–824. doi: 10.1016/S0022-3476(97)70027-1. [DOI] [PubMed] [Google Scholar]
- 12.Korff C, Nordli DR. Do generalized tonic—clonic seizures in infancy exist? Neurology. 2005;65:1750–1753. doi: 10.1212/01.wnl.0000187125.87414.f3. [DOI] [PubMed] [Google Scholar]
- 13.Wyllie E. The treatment of epilepsy: principles and practice. 4th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2006. [Google Scholar]
- 14.Sullivan JE, Dlugos DJ. Antiepileptic drug monotherapy: pediatric concerns. Semin Pediatric Neurol. 2005;12:88–96. doi: 10.1016/j.spen.2005.03.003. [DOI] [PubMed] [Google Scholar]
- 15.U.S. Department of Health and Human Services Food and Drug Administration. Summaries of medical and clinical pharmacology reviews of pediatric studies [Internet]. Created June 18, 2003; updated periodically. Accessed June 19, 2006. Available at: http://www.fda.gov/cder/pediatric/Summaryreview.htm.
- 16.Sahlroot JT, Pledger GW. Reanalysis of existing trial data: what can be learned. Adv Neurol. 1998;76:125–131. [PubMed] [Google Scholar]
- 17.Pina-Garza JE, Espinoza R, Nordli D, et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology. 2005;65:1370–1375. doi: 10.1212/01.wnl.0000186800.18456.72. [DOI] [PubMed] [Google Scholar]
- 18.Nordli DR. Diagnostic difficulty in infants and children. J Child Neurol. 2002;17:S28–S35. doi: 10.1177/08830738020170010401. [DOI] [PubMed] [Google Scholar]
- 19.Motte J, Trevathan E, Arvidsson JFV, Lamictal Lennox-Gastaut Study Group et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. N Engl J Med. 1997;337:1807–1812. doi: 10.1056/NEJM199712183372504. [DOI] [PubMed] [Google Scholar]
- 20.Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology. 1999;52:1882–1887. doi: 10.1212/wnl.52.9.1882. [DOI] [PubMed] [Google Scholar]
- 21.Biton V, Sackellares JC, Vuong A, Hammer AE, Barrett PS, Messenheimer JA. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology. 2005;65:1737–1743. doi: 10.1212/01.wnl.0000187118.19221.e4. [DOI] [PubMed] [Google Scholar]
- 22.Bourgeois B, Brown L, Pellock JM, et al. Gabapentin (Neurontin®) monotherapy in children with benign childhood epilepsy with centrotemporal spikes (BECTS): a 36-week, double-blind, placebo-controlled study. Epilepsia. 1998;39:163–163. doi: 10.1111/j.1528-1157.1998.tb01440.x. [DOI] [Google Scholar]
- 23.Frank LM, Enlow T, Holmes GL, et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia. 1999;40:973–979. doi: 10.1111/j.1528-1157.1999.tb00805.x. [DOI] [PubMed] [Google Scholar]
- 24.Trudeau V, Myers S, LaMoreaux L, Anhut H, Garofalo E, Ebersole J. Gabapentin in naïve childhood absence epilepsy: results from two double-blind, placebo-controlled, multicenter studies. J Child Neurol. 1996;11:470–475. doi: 10.1177/088307389601100611. [DOI] [PubMed] [Google Scholar]
- 25.Mackay MT, Weiss SK, Adams-Webber T, et al. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology. 2004;62:1668–1681. doi: 10.1212/01.wnl.0000127773.72699.c8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Shinnar S, Pellock JM. The trials and tribulations of pediatric drug trials. Neurology. 2005;65:1348–1349. doi: 10.1212/01.wnl.0000183475.81594.29. [DOI] [PubMed] [Google Scholar]
- 27.French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs. II. Treatment of refractory epilepsy. Report of the Therapeutic and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2004;62:1261–1273. doi: 10.1212/01.wnl.0000123695.22623.32. [DOI] [PubMed] [Google Scholar]
- 28.French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs. I. Treatment of new onset epilepsy. Report of the Therapeutic and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2004;62:1252–1260. doi: 10.1212/01.wnl.0000123693.82339.fc. [DOI] [PubMed] [Google Scholar]